Theravance Biopharma (TBPH) Revenue (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Revenue data on file, last reported at $17.7 million in Q1 2026.

• Quarterly Revenue rose 15.02% year-over-year to $17.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.9 million (up 36.19% YoY) and the FY2025 annual result came in at $7.5 million, down 88.35% from the prior year.
• Revenue retreated to $17.7 million in Q1 2026 per TBPH's latest filing, from $25.0 million in the prior quarter.
• Across five years, Revenue topped out at $26.2 million in Q2 2025 and bottomed at $2.5 million in Q1 2022.
• The 5-year median for Revenue is $15.4 million (2025), against an average of $15.7 million.
• The widest annual swing landed in 2022, when Revenue slumped 82.46%; it then soared 316.68% in 2023.
• Tracing TBPH's Revenue over 5 years: stood at $14.6 million in 2022, then advanced by 19.91% to $17.6 million in 2023, then climbed by 6.77% to $18.8 million in 2024, then jumped by 33.3% to $25.0 million in 2025, then slipped by 29.2% to $17.7 million in 2026.
• Per Business Quant, the three latest TBPH Revenue figures stand at $17.7 million (Q1 2026), $25.0 million (Q4 2025), and $20.0 million (Q3 2025).

Peer Comparison